Amantadine

Revision as of 22:02, 8 August 2012 by WikiBot (talk | contribs) (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
Jump to navigation Jump to search

For patient information, please click here

Amantadine
Clinical data
Pregnancy
category
  • C
Routes of
administration
oral
ATC code
Pharmacokinetic data
Bioavailabilitywell absorbed
Protein bindingapprox 67%
Metabolismnegligible
Elimination half-life10-14 hours, in renal impairment up to 7-10 days
Excretionrenal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC10H17N
Molar mass151.249 g/mol

WikiDoc Resources for Amantadine

Articles

Most recent articles on Amantadine

Most cited articles on Amantadine

Review articles on Amantadine

Articles on Amantadine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Amantadine

Images of Amantadine

Photos of Amantadine

Podcasts & MP3s on Amantadine

Videos on Amantadine

Evidence Based Medicine

Cochrane Collaboration on Amantadine

Bandolier on Amantadine

TRIP on Amantadine

Clinical Trials

Ongoing Trials on Amantadine at Clinical Trials.gov

Trial results on Amantadine

Clinical Trials on Amantadine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Amantadine

NICE Guidance on Amantadine

NHS PRODIGY Guidance

FDA on Amantadine

CDC on Amantadine

Books

Books on Amantadine

News

Amantadine in the news

Be alerted to news on Amantadine

News trends on Amantadine

Commentary

Blogs on Amantadine

Definitions

Definitions of Amantadine

Patient Resources / Community

Patient resources on Amantadine

Discussion groups on Amantadine

Patient Handouts on Amantadine

Directions to Hospitals Treating Amantadine

Risk calculators and risk factors for Amantadine

Healthcare Provider Resources

Symptoms of Amantadine

Causes & Risk Factors for Amantadine

Diagnostic studies for Amantadine

Treatment of Amantadine

Continuing Medical Education (CME)

CME Programs on Amantadine

International

Amantadine en Espanol

Amantadine en Francais

Business

Amantadine in the Marketplace

Patents on Amantadine

Experimental / Informatics

List of terms related to Amantadine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Amantadine (1-aminoadamantane, sold as Symmetrel) is an antiviral drug used both as an antiviral and an antiparkinsonic.

Uses

Approved

It was approved by the Food and Drug Administration in 1976 for the treatment of Influenzavirus A in adults. In 1969 the drug was also discovered by accident to help reduce symptoms of Parkinson's disease and drug-induced extrapyramidal syndromes. It is a derivative of adamantane, like rimantadine, a similar drug.

As an antiparkinsonic it can be used as monotherapy; or together with L-DOPA to treat L-DOPA-related motor fluctuations (i.e., shortening of L-DOPA duration of clinical effect, probably related to progressive neuronal loss) and L-DOPA-related dyskinesias (choreiform movements associated with long-term L-DOPA use, probably related to chronic pulsatile stimulation of dopamine receptors).

Off-label uses

There have been anecdotal reports, based on research by Dr. William Singer of Harvard University, that low-dose amantadine has been successfully used to treat ADHD.[1] Amantadine has been shown to relieve SSRI-induced anorgasmia in some people, though not in all people.

Side Effects

Amantadine has been associated with several central nervous system side effects, including nervousness, anxiety, agitation, insomnia, difficulty in concentrating, and exacerbations of pre-existing seizure disorders and psychiatric symptoms in patients with schizophrenia or Parkinson's disease. These side effects are likely due to amantadine's dopaminergic and adrenergic activity, and to a lesser extent, its activity as an anticholinergic.

Cases of suicidal ideation in patients treated with amantadine have been described,[2] although this psychiatric adverse event is relatively rare. Nonetheless, clinical surveillance of suicidal ideation in patients on amantadine is warranted at the clinician's discretion, as amantadine has been implicated as the major fatal (biologically toxic) factor in completed patient suicides.[3]

Another potential side effect is livedo reticularis, a dermatological reaction that results in skin mottling and purpurish mesh network of blood vessels.

Mechanism of its effects

The mechanism of its antiparkinsonic effect is not fully understood, but it appears to be releasing dopamine from the nerve endings of the brain cells, together with stimulation of norepinephrine response. Furthermore, it appears to be a weak NMDA receptor antagonist and an anticholinergic.

The antiviral mechanism seems to be unrelated. The drug interferes with a viral protein, M2 (an ion channel), which is needed for the viral particle to become "uncoated" once it is taken inside the cell by endocytosis.

Misuse

Recently, amantadine is reported to have been used in China poultry farming in an effort to protect the birds against avian influenza.[4] In western countries and according to international livestock regulations, amantadine is approved only for use in humans. Chickens in China have received an estimated 2.6 billion doses of amantadine.[4] Avian flu (H5N1) strains in China and southeast Asia are resistant to amantadine, but strains circulating elsewhere seem to be sensitive. If amantadine resistant strains of the virus spread, the drug of choice in an avian flu outbreak will likely be restricted to one of the scarcer and costlier oseltamivir or zanamivir, which work by a different mechanism and are less likely to trigger resistance.

Declining effectiveness

Early in the 2005/2006 flu season, the United States' Center for Disease Control [CDC] found rates of amantadine resistance to be much higher than in previous seasons. Looking at samples from 26 states yielded the following findings:

A total of 193 (92.3%) of 209 influenza A(H3N2) and 2 (25%) of 8 influenza A(H1N1) viruses analyzed contained point mutations resulting in a serine-to-asparagine change at amino acid 31 (S31N) of the M2 protein that conferred adamantane resistance. [2]

A resistance rate of 92% for the major flu strain was called "alarmingly high". The CDC issued an alert to doctors not to prescribe amantadine any more for the season.[3] Among some Asian countries, A/H3N2 and A/H1N1 resistance has reached 100%.[5]

References

  1. Hallowell, Edward M. and John J. Ratey, Delivered from Distraction: Getting the Most out of Life with Attention Deficit Disorder (2005), pp. 253-5.
  2. Template:Cite paper
  3. Cook et al, "Fatal overdose with amantadine". Can. J. Psychiatry (Nov 1986); 31(8), pp. 757-758.
  4. 4.0 4.1 Sipress, Alan (2005-06-18). "Bird Flu Drug Rendered Useless". Washington Post. pp. A01. Retrieved 2007-08-02.
  5. Deyde, Varough M. (2007-07-15). "Surveillance of Resistance to Adamantanes among Influenza A(H3N2) and A(H1N1) Viruses Isolated Worldwide". Journal of Infectious Diseases. 196 (2): 249–257. Retrieved 2007-08-02. Unknown parameter |coauthors= ignored (help)

See also

Template:Dopaminergic agents

Influenza Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Influenza from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Amantadine On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Amantadine

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Amantadine

CDC on Amantadine

Amantadine in the news

Blogs on Amantadine

Directions to Hospitals Treating Influenza

Risk calculators and risk factors for Amantadine


Template:WikiDoc Sources